Gastric cancer and colorectal cancer have something in common

Share This Post

Researchers at the Duke University Cancer Institute have found that H. pylori may lead to an increased risk of colorectal cancer, especially for people with color. People of color are more likely to be diagnosed and die of colorectal cancer.

The researchers further explored the link between H. pylori and colorectal cancerMore than half of the world’s population is infected with Helicobacter pylori, bacteria can cause gastric cancer and gastric ulcers. Researchers at Duke University collected samples from subjects of different races and checked antibody levels before cancer developed. Half of the more than 8,000 study participants continue to develop colorectal cancer. To determine whether the presence of antibodies increased the likelihood of developing colorectal cancer, the researchers compared the frequency of antibodies between cancer and non-cancer subjects. They observed similar rates of past infections in the two groups. As a result, a higher percentage of black and Latino subjects had H. pylori antibodies. This finding is consistent in both cancer and non-cancer tissues. Antibodies specific for Helicobacter pylori proteins are most commonly found in different ethnic groups. Most importantly, a high-level antibody to the H. pylori protein-VacA protein is closely related to the incidence of colorectal cancer in African-American and Asian Americans. 

The association between H. pylori and colorectal cancer plays a role in people of color and can significantly affect treatment options, action plans, and public health differences related to cancer. Medical professionals can identify high-risk people with colorectal cancer based on the status of Helicobacter pylori and reduce the incidence of cancer through treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy